Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
US10966977B2 · kind B2 · utility
4Cited by
6References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 26, 2017 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | May 26, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for inhibiting proliferation of a B-cell population are provided comprising administering a combination of agents, comprising: (i) at least one P13K-delta selective inhibitor; (ii) at least one anti-CD20 antibody; and (iii) at least one Bruton's tyrosine kinase (BTK) inhibitor. Methods for treating B-cell proliferative disorders, such as B-cell hematological malignancies, as well as kits for carrying out the claimed methods, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.